Stanford, CANCT05957536Now EnrollingIRB Ready

HER-2 Positive Advanced Solid Tumors Clinical Trial in Stanford, CA

Access cutting-edge her-2 positive advanced solid tumors treatment through this clinical trial at a research site in Stanford. Study-provided care at no cost to qualified participants.

Sponsored by D3 Bio (Wuxi) Co., Ltd

Quick Self-Assessment

See if you qualify for this Stanford location

Preparing your pre-screening questions…

Expert Care in Stanford

Access her-2 positive advanced solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related her-2 positive advanced solid tumors treatment provided free

Apply for This Stanford Location

Check if you qualify for this her-2 positive advanced solid tumors clinical trial in Stanford, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Stanford

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Stanford site if eligible
  4. 4Begin participation

About This HER-2 Positive Advanced Solid Tumors Study in Stanford

This first-in-human (FIH) study, multi-center, open-label, dose escalation and dose expansion Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary anti-tumor activity of D3L-001 in subjects with HER2-positive advanced solid tumors.

Sponsor: D3 Bio (Wuxi) Co., Ltd

Who Can Participate

Inclusion Criteria

Subject must have documented HER2 positivity (determined by immunohistochemistry \[IHC\], in situ hybridization \[ISH\], Next Generation Sequencing \[NGS\] or other analysis techniques as appropriate).
Subject must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Subject must have left ventricular ejection fraction (LVEF) ≥50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within the screening period.
Subject must have adequate organ and marrow function within the screening period.

Exclusion Criteria

Subject has any prior treatment with anti-CD47 or SIRPα agent.
Subject has any prior treatment without adequate washout periods as defined in the protocol.
Subject has immunosuppressive medication that is not completed 14 days before the first dose of study medication.
Subject has uncontrolled intercurrent illness that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the subject to give written informed consent.
Subject has unresolved treatment-related toxicities from previous anticancer therapy of NCI CTCAE Grade ≥2 (with exception of vitiligo or alopecia).
Judgment by the Investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions, and requirements.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Stanford?

Yes, this clinical trial (NCT05957536) has an active research site in Stanford, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

HER-2 Positive Advanced Solid Tumors Treatment Options in Stanford, CA

If you're searching for her-2 positive advanced solid tumors treatment options in Stanford, CA, this clinical trial (NCT05957536) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Stanford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced her-2 positive advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all her-2 positive advanced solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Stanford, CA

See all advanced solid tumors clinical trials recruiting in Stanford — not just this study.

Browse Advanced Solid Tumors Trials in Stanford →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Stanford?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Stanford, CA